Single-fraction canine brain SRS shows tumor responses but higher-dose neurological injury concerns
In dogs with presumed glioma, single-fraction 10 Gy reduced MRI-defined tumor volume, while 15 Gy was associated with suspected radiation injury.
In dogs with presumed glioma, single-fraction 10 Gy reduced MRI-defined tumor volume, while 15 Gy was associated with suspected radiation injury.
In 271 recurrent glioblastoma patients, SRS doses above 19 Gy were associated with longer post-recurrence survival, without a demonstrated progression-free survival benefit.
In 18 salvage surgery patients, favorable facial nerve function persisted in most, but postoperative deterioration occurred after both irradiation-only and combined treatment histories.
Among 879 SRS programs, 91% treated multiple lesions, while only 18.8% reported additional machine-specific QA for multi-lesion treatments.
A PTV-dependent V50% threshold flagged 10% of clinical SRS plans, with replanning reducing excess intermediate-dose exposure by a median 14%.
A model using target volume and HyTEC limits estimated automated SRS prescription doses with approximately 1.3% mean absolute error.
Memantine preserved 6-month cognition versus placebo after radiotherapy for brain metastases, with benefits also seen in quality of life.
Treatment failure at one year was 14.4% at 2400 MU/min versus 42.7% at 800 MU/min, with similar facial numbness.
Distal targeting produced more overall pain relief, while proximal targeting yielded more complete pain freedom and medication discontinuation.
Enhanced leaf and optimized DLG models produced similarly accurate SRS dose calculations, with DLG showing a small QA advantage.
Large cystic Koos III–IV vestibular schwannomas showed greater early shrinkage after SRS, with 100% local control in 15 cystic cases.
Across 14 studies, repeat stereotactic radiotherapy achieved 76% one-year local control, but symptomatic radiation necrosis occurred in 10%.
Environ showed less static-beam attenuation and lower vertical setup variability than Encompass while maintaining accurate HyperArc dose calculation.
Gamma Knife and LINAC radiosurgery produced similarly high control and low new neurologic symptoms in 85 vestibular schwannoma patients.
KRAS-mutant and wild-type NSCLC showed similar intracranial control after SRS, while higher radiation dose predicted better outcomes.